Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives
Open accessThe DOI matches its Crossref record; 301 of the 301 references it cites were found in a registry or an index.
Abstract
Parkinsonism is a progressive motor disease that affects 1.5 million Americans and is the second most common neurodegenerative disease after Alzheimer’s. Typical neuropathological features of Parkinson’s disease (PD) include degeneration of dopaminergic neurons located in the pars compacta of the substantia nigra that project to the striatum (nigro-striatal pathway) and depositions of cytoplasmic fibrillary inclusions (Lewy bodies) which contain ubiquitin and α-synuclein. The cardinal motor signs of PD are tremors, rigidity, slow movement (bradykinesia), poor balance, and difficulty in walking (Parkinsonian gait). In addition to motor symptoms, non-motor symptoms that include autonomic and psychiatric as well as cognitive impairments are pressing issues that need to be addressed. Several different mechanisms play an important role in generation of Lewy bodies; endoplasmic reticulum (ER) stress induced unfolded proteins, neuroinflammation and eventual loss of dopaminergic neurons in the substantia nigra of mid brain in PD. Moreover, these diverse processes that result in PD make modeling of the disease and evaluation of therapeutics against this devastating disease difficult. Here, we will discuss diverse mechanisms that are involved in PD, neuroprotective and therapeutic strategies currently in clinical trial or in preclinical stages, and impart views about strategies that are promising to mitigate PD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 1×
“The brain requires constant oxygen at a significantly high rate; thus, the presence of these free radicals and low amounts of antioxidant molecules present in the brain make the brain more vulnerable to oxidative damage [52].”
BackgroundStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Lewy bodies first appear in the periphery [41], subsequently it travels to brain stem and eventually in the cortex.”
BackgroundThe functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353 · cited 2×
“Recent ablation studies in animal model of PD and the introduction of the deep brain stimulation technique revolutionized our ability to comprehend about the pathogenesis of PD [15–17,207,208].”
BackgroundMethodMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 3×
“Studies suggest that most of the point mutations are extremely rare and not likely to contribute any major role in PD pathogenesis although parkin mutations are quite prevalent in early onset of PD [71,172,173] and LRRK2 mutations contribute to cause 2% of the sporadic aspects of PD [174,175].”
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914 · cited 1×
“Complex I inhibition has been documented in the substantia nigra of humans afflicted with PD [55], and other complex I inhibitors including MPP+ and rotenone have been documented in in vivo model of PD [56–58].”
BackgroundNicholson, J. K., Lindon, J. C., & Holmes, E. (1999) · Xenobiotica · doi:10.1080/004982599238047 · Cited by 3,895
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824 · cited 2×
“Recent ablation studies in animal model of PD and the introduction of the deep brain stimulation technique revolutionized our ability to comprehend about the pathogenesis of PD [15–17,207,208].”
BackgroundMethodChronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683 · cited 1×
“Complex I inhibition has been documented in the substantia nigra of humans afflicted with PD [55], and other complex I inhibitors including MPP+ and rotenone have been documented in in vivo model of PD [56–58].”
BackgroundFrequency Dependence of Signal Power and Spatial Reach of the Local Field Potential
Leski, S., Lindén, H., Tetzlaff, T., Pettersen, K. H., & Einevoll, G. T. (2013) · PubMed · doi:10.18154/rwth-conv-084442 · Cited by 3,639
Ames, B. N., Cathcart, R., Schwiers, E., & Hochstein, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.6858 · Cited by 2,909 · cited 1×
“Basically, uric acid can prevent generation of oxidative free radicals and free nitrogen species to prevent further oxidative stress [187].”
BackgroundSpillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868 · cited 1×
“This toxic protein, Lewy bodies, is made of different proteins such as α-synuclein [37,38], synphilin-1 [39], and ubiquitin [40].”
BackgroundNon-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 1×
“However, we cannot rule out the possibility that not only PD pathology is confined to the degeneration of dopaminergic neurons but also include non-motor such as cognitive impairment, hallucinations and other disturbances due to dysfunction of autonomic nervous system also play major role(s) in the array of impairment…”
BackgroundHummel, T., Sekinger, B., Wolf, S. R., Pauli, E., & Kobal, G. (1997) · Chemical Senses · doi:10.1093/chemse/22.1.39 · Cited by 2,501 · cited 1×
“exploited to demarcate from other neurological diseases such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) but not from multiple system atrophy (MSA) [255,260,261].”
BackgroundTransplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984 · cited 1×
“Recent studies showed that imaging techniques that target activated microglia are certainly upregulated in the human brain that are inflicted with PD [275–277] although the efficacy and usefulness of this approach will rely on specificity and sensitivity of the ligand targeted for different markers.”
BackgroundReversal of Experimental Parkinsonism by Lesions of the Subthalamic Nucleus
Bergman, H., Wichmann, T., & DeLong, M. R. (1990) · Science · doi:10.1126/science.2402638 · Cited by 1,907 · cited 1×
“Recent ablation studies in animal model of PD and the introduction of the deep brain stimulation technique revolutionized our ability to comprehend about the pathogenesis of PD [15–17,207,208].”
BackgroundKriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,907 · cited 1×
“By using stringent procedures, it is certainly attainable to differentiate dopaminergic neurons which have chemical phenotype that of human brain, moreover, this ESC can also withstand procedures involved in grafting and certainly have the ability to regain control of movement of limbs in in vivo models of PD [290–292…”
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821 · cited 1×
“While replacement of the dopamine deficit with levodopa is an accepted treatment for PD, only ~25% of patients treated with this agent for 5 years continue to enjoy a good response; the remainder suffers from motor fluctuations and involuntary movements [126,127].”
BackgroundThe Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788 · cited 1×
“Recently, it has been demonstrated in humans that PTEN-induced putative kinase (PINK1) and DJ-1 [66–68] are the genes involved in inducing familial forms of PD and also involved in reducing stress due to oxidative free radical production.”
BackgroundMITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738 · cited 1×
“However, we cannot rule out the possibility that not only PD pathology is confined to the degeneration of dopaminergic neurons but also include non-motor such as cognitive impairment, hallucinations and other disturbances due to dysfunction of autonomic nervous system also play major role(s) in the array of impairment…”
BackgroundMitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 1×
“Recently, it has been demonstrated in humans that PTEN-induced putative kinase (PINK1) and DJ-1 [66–68] are the genes involved in inducing familial forms of PD and also involved in reducing stress due to oxidative free radical production.”
BackgroundParkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571 · cited 1×
“Recent evidence suggests there are two proteins that are linked to genetic forms of PD such parkin and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), and further confirms the association between formation of misfolded protein and development of PD [71,74].”
BackgroundRascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539 · cited 1×
“and pramipexole [12,13].”
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Goetz, C. G., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stebbins, G. T., Stern, M. B., Tilley, B. C., Dodel, R., Dubois, B., et al. (2007) · Movement Disorders · doi:10.1002/mds.21198 · Cited by 1,404
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · cited 1×
“It is also plausible that excessive iron content as seen in human PD could induce cell death due to presence of free oxidative radicals [54,62].”
BackgroundFunctional Repression of cAMP Response Element in 6-Hydroxydopamine-treated Neuronal Cells
Chalovich, E. M., Zhu, J.-H., Caltagarone, J., Bowser, R., & Chu, C. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602632200 · Cited by 1,371
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307 · cited 6×
“In the study involving human PD subjects, no significant improvement was noticed and graft-induced medication-independent dyskinesia developed [22].”
BackgroundMethodInfluentialDirect brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290 · cited 1×
“While the clinical trial using GDNF has been concluded in human trials [119,120], neurturin is still in Phase II trial.”
BackgroundDeep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease
Benabid, A. L., Chabardes, S., Mitrofanis, J., & Pollak, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70291-6 · Cited by 1,285
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278 · cited 1×
“It was in 1960s when it was discovered that dopamine present in the striatum is responsible for motor symptoms of PD [2,3].”
BackgroundZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 1×
“In in vitro studies, it has been recently been reported that different chemical conformation such as nitrated and aggregated forms of α-synuclein can induce microglial activation and eventually release more chemicals that are toxic to cells [88–91].”
BackgroundKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“One such trophic factor is glial cell derived neurotrophic factor or GDNF that nourishes dopamine synthesizing neurons of the substantia nigra [116,154].”
BackgroundBlum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., & Verna, J.-M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246 · cited 1×
“Cell death due to apoptosis has been well established in in vivo PD models [111,112].”
BackgroundEffects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199 · cited 1×
“The degeneration of dopaminergic neurons in the substantia nigra lead to PD [36].”
BackgroundApoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M. T., Michel, P. P., Marquez, J., Prigent, A., Ruberg, M., Hirsch, É. C., & Agid, Y. (1997) · PubMed · Cited by 1,188
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 1×
“Minocycline has found to be neuroprotective in chemically induced in vivo models of PD [184–186].”
BackgroundWang, E.-S., Yao, H.-B., Chen, Y.-H., Wang, G., Gao, W.-W., Sun, Y.-R., Guo, J.-G., Hu, J.-W., Jiang, C.-C., & Hu, J. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350082 · Cited by 1,176
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161 · cited 1×
“Glutathione, an antioxidant protein found in its reduced form in the mid brain substantia nigra of human PD [63–65] suggesting damage of the anti-oxidative system in human.”
BackgroundUnderstanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism
Nicholson, J. K., & Wilson, I. D. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1157 · Cited by 1,116 · cited 1×
“[281].”
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067 · cited 1×
“There are two anatomical areas that have been targeted to evaluate: one is STN where the AAV vector could be used to infuse enzyme GAD which has the ability to transform neurons that are glutamatergic in nature into GABA synthesizing neurons [240,241], and another region is the caudate putamen where this viral vectors…”
BackgroundBilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
Rodriguez-Oroz, M. C., Obeso, J. A., Lang, A. E., Houeto, J.-L., Pollak, P., Rehncrona, S., Kulisevsky, J., Albanese, A., Volkmann, J., Hariz, M. I., et al. (2005) · Brain · doi:10.1093/brain/awh571 · Cited by 1,057 · cited 1×
“It has recently been documented that DBS performed either unilaterally or bilaterally improves parkinsonian motor signs [209,211–214].”
BackgroundSydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y., & Takahashi, R. (2001) · Cell · doi:10.1016/s0092-8674(01)00407-x · Cited by 1,050
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986 · cited 1×
“It has also been found that pro-inflammatory cytokines such as IL-1beta, IL-6, and TNF-α are increased in the CSF and basal ganglia of PD patients [83–85].”
BackgroundEffects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983 · cited 2×
“In human trials, GDNF was infused directly into the brain but a large clinical trial was not continued due to lack of any positive outcome [120].”
BackgroundDeep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Bronstein, J. M., Tagliati, M., Alterman, R. L., Lozano, A. M., Volkmann, J., Stefani, A., Horak, F. B., Okun, M. S., Foote, K. D., Krack, P., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.260 · Cited by 971 · cited 1×
“These procedures are best suited for PD patients that have previously improved on levodopa and are free of dementia, or other psychiatric co-morbidities [209,210].”
BackgroundWilliam Langston, J., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922 · cited 1×
“Complex I inhibition has been documented in the substantia nigra of humans afflicted with PD [55], and other complex I inhibitors including MPP+ and rotenone have been documented in in vivo model of PD [56–58].”
BackgroundEffect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883 · cited 1×
“Although the exact mechanism of mitochondrial dysfunction is not known, it is plausible that mutation of either inherited or acquired mutations in mitochondrial DNA are responsible [59–61].”
Background[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].
Birkmayer, W., & Hornykiewicz, O. (1961) · PubMed · Cited by 870
Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855 · cited 1×
“It has also been found that pro-inflammatory cytokines such as IL-1beta, IL-6, and TNF-α are increased in the CSF and basal ganglia of PD patients [83–85].”
BackgroundAlam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845 · cited 1×
“Increased amount of lipid peroxidation and molecules related to oxidative stress has been demonstrated in the human PD brain [53,54].”
BackgroundMicroglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843 · cited 1×
“Recent studies showed that imaging techniques that target activated microglia are certainly upregulated in the human brain that are inflicted with PD [275–277] although the efficacy and usefulness of this approach will rely on specificity and sensitivity of the ligand targeted for different markers.”
BackgroundDoty, R. L., Deems, D. A., & Stellar, S. (1988) · Neurology · doi:10.1212/wnl.38.8.1237 · Cited by 838
Direct and indirect pathways of basal ganglia: a critical reappraisal
Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., & Di Filippo, M. (2014) · Nature Neuroscience · doi:10.1038/nn.3743 · Cited by 828 · cited 2×
“Around 90% of the striatal cells are spiny projected neurons and inhibitory and they have either D1 or D2 dopamine receptors and innervate distinct target nuclei [43].”
BackgroundDu, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789 · cited 1×
“Minocycline has found to be neuroprotective in chemically induced in vivo models of PD [184–186].”
BackgroundA common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774 · cited 1×
“Studies suggest that most of the point mutations are extremely rare and not likely to contribute any major role in PD pathogenesis although parkin mutations are quite prevalent in early onset of PD [71,172,173] and LRRK2 mutations contribute to cause 2% of the sporadic aspects of PD [174,175].”
BackgroundIdiopathic hyposmia as a preclinical sign of Parkinson's disease
Ponsen, M. M., Stoffers, D., Booij, J., van Eck‐Smit, B. L. F., Wolters, E. C., & Berendse, H. W. (2004) · Annals of Neurology · doi:10.1002/ana.20160 · Cited by 740 · cited 1×
“This combined approach (SPECT DAT imaging with smell loss) has been used recently to identify individuals who have a high risk of developing PD [273,274].”
MethodParkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Kim, R. H., Smith, P. D., Aleyasin, H., Hayley, S., Mount, M. P., Pownall, S., Wakeham, A., You-Ten, A. J., Kalia, S. K., Horne, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501282102 · Cited by 701 · cited 1×
“Recently, it has been demonstrated in humans that PTEN-induced putative kinase (PINK1) and DJ-1 [66–68] are the genes involved in inducing familial forms of PD and also involved in reducing stress due to oxidative free radical production.”
BackgroundLeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681 · cited 1×
“There are two anatomical areas that have been targeted to evaluate: one is STN where the AAV vector could be used to infuse enzyme GAD which has the ability to transform neurons that are glutamatergic in nature into GABA synthesizing neurons [240,241], and another region is the caudate putamen where this viral vectors…”
BackgroundSystematic evaluation of rating scales for impairment and disability in Parkinson's disease
Ramaker, C., Marinus, J., Stiggelbout, A. M., & van Hilten, B. J. (2002) · Movement Disorders · doi:10.1002/mds.10248 · Cited by 666 · cited 1×
“Although the UDPRS system has been quite commonly used to monitor motor function, this system is not foolproof and there are several flaws in the UDPRS scaling system [164,165].”
MethodKirkeby, A., Grealish, S., Wolf, D. A., Nelander, J., Wood, J., Lundblad, M., Lindvall, O., & Parmar, M. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.04.009 · Cited by 662 · cited 1×
“By using stringent procedures, it is certainly attainable to differentiate dopaminergic neurons which have chemical phenotype that of human brain, moreover, this ESC can also withstand procedures involved in grafting and certainly have the ability to regain control of movement of limbs in in vivo models of PD [290–292…”
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
A Fluorimetric Method for the Determination of Dopamine (3‐Hydroxytyramine.)
CARLSSON, A., & WALDECK, B. (1958) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1958.tb01628.x · Cited by 625 · cited 1×
“It was in 1960s when it was discovered that dopamine present in the striatum is responsible for motor symptoms of PD [2,3].”
BackgroundChen, L., & Feany, M. B. (2005) · Nature Neuroscience · doi:10.1038/nn1443 · Cited by 618 · cited 1×
“Recent evidence also suggests that chemical changes such as oxidation and phosphorylation are essential for accumulation of misfolded protein, α-synuclein [195–197].”
BackgroundTreatment of Parkinsonism With Levodopa
Yahr, M. D., Duvoisin, R. C., Schear, M. J., Barrett, R. E., & Hoehn, M. M. (1969) · Archives of Neurology · doi:10.1001/archneur.1969.00480160015001 · Cited by 604 · cited 1×
“Currently, L-DOPA still maintains the forefront of dopamine replacement therapy over 40 years of its development [122].”
BackgroundMarks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Animal models of Parkinson's disease
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2002) · BioEssays · doi:10.1002/bies.10067 · Cited by 592
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
Sofic, E., Lange, K. W., Jellinger, K., & Riederer, P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90355-b · Cited by 590 · cited 1×
“Glutathione, an antioxidant protein found in its reduced form in the mid brain substantia nigra of human PD [63–65] suggesting damage of the anti-oxidative system in human.”
BackgroundTansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 583 · cited 2×
“One of the key features of PD pathology is neuroinflammation [80–82].”
BackgroundThe parkinson's complex: Parkinsonism is just the tip of the iceberg
Langston, J. W. (2006) · Annals of Neurology · doi:10.1002/ana.20834 · Cited by 583
Funkiewiez, A. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2002.009803 · Cited by 572 · cited 1×
“Recent studies suggest that DBS may cause manic depression, induce emotional instability and suicidal thoughts [221,223,225–230].”
BackgroundDityrosine Cross-linking Promotes Formation of Stable α-Synuclein Polymers
Souza, J. M., Giasson, B. I., Chen, Q., Lee, V. M.-Y., & Ischiropoulos, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000206200 · Cited by 563
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists
Turski, L., Bressler, K., Jürgen Rettig, K., Löschmann, P.-A., & Wachtel, H. (1991) · Nature · doi:10.1038/349414a0 · Cited by 546
Okun, M. S., Fernandez, H. H., Wu, S. S., Kirsch‐Darrow, L., Bowers, D., Bova, F., Suelter, M., Jacobson, C. E., Wang, X., Gordon, C. W., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21596 · Cited by 545 · cited 1×
“Recent studies suggest that DBS may cause manic depression, induce emotional instability and suicidal thoughts [221,223,225–230].”
BackgroundEffects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542 · cited 1×
“[194].”
Kachergus, J., Mata, I. F., Hulihan, M., Taylor, J. P., Lincoln, S., Aasly, J., Gibson, J. M., Ross, O. A., Lynch, T., Wiley, J., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429256 · Cited by 541 · cited 1×
“Studies suggest that most of the point mutations are extremely rare and not likely to contribute any major role in PD pathogenesis although parkin mutations are quite prevalent in early onset of PD [71,172,173] and LRRK2 mutations contribute to cause 2% of the sporadic aspects of PD [174,175].”
BackgroundProtein Nitration in Parkinsonʼs Disease
Good, P. F., Hsu, A., Werner, P., Perl, D. P., & Olanow, C. W. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199804000-00006 · Cited by 540 · cited 1×
“Thus, it is quite normal that 3-Nitrotyrosine, has been found to be abnormally higher in SN of PD patients [102].”
BackgroundPallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Anderson, V. C., Burchiel, K. J., Hogarth, P., Favre, J., & Hammerstad, J. P. (2005) · Archives of Neurology · doi:10.1001/archneur.62.4.554 · Cited by 537 · cited 1×
“Although there is a perception that STN could be a better target than GPi, recent large randomized clinical trials comparing GPi and STN-DBS did not find any significant difference in terms of motor side effects of the procedures [211,231].”
Activation of the unfolded protein response in Parkinson’s disease
Hoozemans, J. J. M., van Haastert, E. S., Eikelenboom, P., de Vos, R. A. I., Rozemuller, J. M., & Scheper, W. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.043 · Cited by 525 · cited 2×
“Recently, two markers of ER stress pPERK and pEIF2α have been observed in neurons of substantia nigra of human that afflicted with PD [70].”
BackgroundHsp70 Reduces α-Synuclein Aggregation and Toxicity
Klucken, J., Shin, Y., Masliah, E., Hyman, B. T., & McLean, P. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400255200 · Cited by 508 · cited 2×
“Recently, it has been demonstrated that key substrates play an important role in protein turnover and degradation and it is HSP70 that has the capability to modulate toxicity induced by α-synuclein [75,76].”
BackgroundDawson, V. L., & Dawson, T. M. (1996) · Journal of Chemical Neuroanatomy · doi:10.1016/0891-0618(96)00148-2 · Cited by 498 · cited 1×
“To induce cell death, glutamate may increase the intra-cellular calcium level following NMDA receptor activation [100] followed by peroxynitrite production [101].”
BackgroundAxon degeneration in Parkinson's disease
Burke, R. E., & O'Malley, K. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.011 · Cited by 493 · cited 1×
“The recent studies from experimental PD models and human clinical trials support the notion that PD pathology originates in the axon terminal [49].”
BackgroundA Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 472 · cited 1×
“In human clinical trials, it has been shown that the risk of having PD can be decreased by around 45% if NSAID has been taken regularly [96] and a subsequent study carried out by the same investigators showed that ibuprofen could be used as a neuroprotectant [177].”
BackgroundA multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease
Voon, V., Krack, P., Lang, A. E., Lozano, A. M., Dujardin, K., Schüpbach, M., D’Ambrosia, J., Thobois, S., Tamma, F., Herzog, J., et al. (2008) · Brain · doi:10.1093/brain/awn214 · Cited by 472 · cited 1×
“Recent studies suggest that DBS may cause manic depression, induce emotional instability and suicidal thoughts [221,223,225–230].”
BackgroundMoro, E., Lozano, A. M., Pollak, P., Agid, Y., Rehncrona, S., Volkmann, J., Kulisevsky, J., Obeso, J. A., Albanese, A., Hariz, M. I., et al. (2010) · Movement Disorders · doi:10.1002/mds.22735 · Cited by 468 · cited 1×
“Although there is a perception that STN could be a better target than GPi, recent large randomized clinical trials comparing GPi and STN-DBS did not find any significant difference in terms of motor side effects of the procedures [211,231].”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445 · cited 1×
“There are two anatomical areas that have been targeted to evaluate: one is STN where the AAV vector could be used to infuse enzyme GAD which has the ability to transform neurons that are glutamatergic in nature into GABA synthesizing neurons [240,241], and another region is the caudate putamen where this viral vectors…”
BackgroundGhosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., & Pahan, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704908104 · Cited by 438 · cited 1×
“In a mouse model of PD, it has been shown that α-synuclein or modified forms of protein can induce both microglial and humoral responses [92,93], and when NF-KB signaling was inhibited by a chemical, it can protect the dopaminergic neurons [94].”
BackgroundLiving on the edge with too many mouths to feed: Why dopamine neurons die
Bolam, J. P., & Pissadaki, E. K. (2012) · Movement Disorders · doi:10.1002/mds.25135 · Cited by 436 · cited 1×
“Another plausible mechanism is that aberrant striatal function could lead to axon degeneration and eventually result in neuronal loss [47,48].”
BackgroundStiasny-Kolster, K. (2004) · Brain · doi:10.1093/brain/awh322 · Cited by 430 · cited 1×
“This combined approach (SPECT DAT imaging with smell loss) has been used recently to identify individuals who have a high risk of developing PD [273,274].”
MethodStimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up
Schupbach, W. M. M. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.063206 · Cited by 425
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Lee Mosley, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 420
A controlled trial of antidepressants in patients with Parkinson disease and depression
Menza, M., Dobkin, R. D., Marin, H., Mark, M. H., Gara, M., Buyske, S., Bienfait, K., & Dicke, A. (2009) · Neurology · doi:10.1212/01.wnl.0000336340.89821.b3 · Cited by 414 · cited 1×
“Only one human study involving 52 PD patients with depression suggests that TCA nortriptyline, which is a non-specific norepinephrine reuptake blocker (SNRI), seems to be more efficacious than the SSRI paroxetine CR in reducing depression in PD [206].”
BackgroundLewy bodies are ubiquitinated: A light and electron microscopic immunocytochemical study
Kuzuhara, S., Mori, H., Izumiyama, N., Yoshimura, M., & Ihara, Y. (1988) · Acta Neuropathologica · doi:10.1007/bf00687787 · Cited by 410
Duan, W., Ladenheim, B., Cutler, R. G., Kruman, I. I., Cadet, J. L., & Mattson, M. P. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00676.x · Cited by 405 · cited 2×
“In vitro studies suggest that uric can prevent degeneration of dopamine neurons when exposed to toxin, rotenone [183].”
BackgroundMetabolomic profiling to develop blood biomarkers for Parkinson's disease
Bogdanov, M., Matson, W. R., Wang, L., Matson, T., Saunders-Pullman, R., Bressman, S. S., & Beal, M. F. (2008) · Brain · doi:10.1093/brain/awm304 · Cited by 401 · cited 1×
“have combined HPLC with electrochemical colorimetric method to evaluate possible biomarkers in plasma samples from patients inflicted with PD [285].”
MethodOlfactory dysfunction in Parkinson's disease.
Hawkes, C. H., Shephard, B. C., & Daniel, S. E. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.5.436 · Cited by 396
Irizarry, M. C., Growdon, W., Gomez-isla, T., Newell, K., George, J. M., Clayton, D. F., & Hyman, B. T. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199804000-00005 · Cited by 394 · cited 1×
“This toxic protein, Lewy bodies, is made of different proteins such as α-synuclein [37,38], synphilin-1 [39], and ubiquitin [40].”
BackgroundMogi, M., Togari, A., Kondo, T., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., & Nagatsu, T. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00463-2 · Cited by 392 · cited 1×
“These factors such as BDNF [114], GDNF [115], and NGF [114], have all been found to be dramatically decreased in the nigra of human brain inflicted with PD.”
BackgroundCorrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P., & Ungerstedt, U. (1973) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1973.tb10037.x · Cited by 392 · cited 1×
“Due to the complications associated with levodopa, new drugs in the form of dopamine receptor agonists have been developed for patients who have the early stages of PD; these dopamine receptor agonists confer anti-PD therapy with relatively low risk of developing dyskinesia [9–11].”
BackgroundParkinson’s disease: The non-motor issues
Chaudhuri, K. R., Odin, P., Antonini, A., & Martinez-Martin, P. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.02.018 · Cited by 388
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
Wolozin, B., Wang, S. W., Li, N.-C., Lee, A., Lee, T. A., & Kazis, L. E. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-20 · Cited by 383
The role of radiotracer imaging in Parkinson disease
Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149403.14458.7f · Cited by 374
Olfactory function in patients with Parkinson's disease
Ansari, K. A., & Johnson, A. (1975) · Journal of Chronic Diseases · doi:10.1016/0021-9681(75)90058-2 · Cited by 373 · cited 1×
“It has been 30 years since the association between olfactory dysfunction and PD was first reported [247], and since then a plethora of studies have been conducted and some studies suggest that anosmia pay precede the onset of motor disease [248–250].”
ResultCreatine and Cyclocreatine Attenuate MPTP Neurotoxicity
Matthews, R. T., Ferrante, R. J., Klivenyi, P., Yang, L., Klein, A. M., Mueller, G., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7049 · Cited by 373 · cited 1×
“Creatine has been shown to have neuroprotective effects and promotes mitochondrial ATP production in animal models [149].”
BackgroundResults from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370 · cited 1×
“There are two anatomical areas that have been targeted to evaluate: one is STN where the AAV vector could be used to infuse enzyme GAD which has the ability to transform neurons that are glutamatergic in nature into GABA synthesizing neurons [240,241], and another region is the caudate putamen where this viral vectors…”
BackgroundTheodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 367 · cited 1×
“In a mouse model of PD, it has been shown that α-synuclein or modified forms of protein can induce both microglial and humoral responses [92,93], and when NF-KB signaling was inhibited by a chemical, it can protect the dopaminergic neurons [94].”
BackgroundNitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons
Benner, E. J., Banerjee, R., Reynolds, A. D., Sherman, S., Pisarev, V. M., Tsiperson, V., Nemachek, C., Ciborowski, P., Przedborski, S., Mosley, R. L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001376 · Cited by 362 · cited 1×
“In a mouse model of PD, it has been shown that α-synuclein or modified forms of protein can induce both microglial and humoral responses [92,93], and when NF-KB signaling was inhibited by a chemical, it can protect the dopaminergic neurons [94].”
BackgroundPerry, T. L., & Yong, V. W. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90320-4 · Cited by 361 · cited 1×
“Glutathione, an antioxidant protein found in its reduced form in the mid brain substantia nigra of human PD [63–65] suggesting damage of the anti-oxidative system in human.”
BackgroundHe, Y., Appel, S., & Le, W. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02681-6 · Cited by 348 · cited 1×
“Minocycline has found to be neuroprotective in chemically induced in vivo models of PD [184–186].”
BackgroundDoes levodopa slow or hasten the rate of progression of Parkinson’s disease?
Fahn, S., & and the Parkinson Study Group (2005) · Journal of Neurology · doi:10.1007/s00415-005-4008-5 · Cited by 347 · cited 1×
“and pramipexole [12,13].”
Björklund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C., & Mandel, R. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02915-2 · Cited by 346
The role of α-synuclein in Parkinson's disease: insights from animal models
Maries, E., Dass, B., Collier, T. J., Kordower, J. H., & Steece-Collier, K. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1199 · Cited by 344 · cited 1×
“Due to variation in displaying several important features of PD such as a-synuclein inclusion or TH loss and inability to show significant loss of TH neurons in the substantia nigra, these genetic models are not suitable for PD study [168,171].”
BackgroundSteiner, J. P., Connolly, M. A., Valentine, H. L., Hamilton, G. S., Dawson, T. M., Hester, L., & Snyder, S. H. (1997) · Nature Medicine · doi:10.1038/nm0497-421 · Cited by 341 · cited 1×
“Neuroimmunophilins are proteins that have strong affinity to immunosuppressive drugs and also present in great amount in the brain and induce growth of the neurons [159–161].”
BackgroundNeurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons
Horger, B. A., Nishimura, M. C., Armanini, M. P., Wang, L.-C., Poulsen, K. T., Rosenblad, C., Kirik, D., Moffat, B., Simmons, L., Johnson, E., et al. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-13-04929.1998 · Cited by 338
Olfactory loss may be a first sign of idiopathic Parkinson's disease
Haehner, A., Hummel, T., Hummel, C., Sommer, U., Junghanns, S., & Reichmann, H. (2007) · Movement Disorders · doi:10.1002/mds.21413 · Cited by 333
Hebron, M. L., Lonskaya, I., & Moussa, C. E. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt192 · Cited by 325
NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release
Mody, I. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)89070-7 · Cited by 324
Lo Bianco, C., Schneider, B. L., Bauer, M., Sajadi, A., Brice, A., Iwatsubo, T., & Aebischer, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405313101 · Cited by 322 · cited 1×
“An increase in the level of parkin or UCH-L1 can help increase the clearance of α-synuclein as recent evidence suggests that overexpression of parkin can prevent aggregation of α -synuclein in in vivo models of PD [190–192].”
BackgroundDexter, D. T., Sian, J., Rose, S., Hindmarsh, J. G., Mann, V. M., Cooper, J. M., Wells, F. R., Daniel, S. E., Lees, A. J., Schapira, A. H. V., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410350107 · Cited by 317 · cited 2×
“It is also plausible that excessive iron content as seen in human PD could induce cell death due to presence of free oxidative radicals [54,62].”
BackgroundSerotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants
Politis, M., Wu, K., Loane, C., Quinn, N. P., Brooks, D. J., Rehncrona, S., Bjorklund, A., Lindvall, O., & Piccini, P. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000976 · Cited by 316 · cited 1×
“This notion was further confirmed by another set of experiments where it has been shown that chronic injection of buspirone, decreases neuronal activity of serotonin, and ameliorates transplant related dyskinesia in patients inflicted with PD and also in rat models of PD [234–236] although the efficacy in preventing P…”
ResultHuisman, E., Uylings, H. B. M., & Hoogland, P. V. (2004) · Movement Disorders · doi:10.1002/mds.10713 · Cited by 313 · cited 1×
“While a few studies suggest degeneration of olfactory epithelium of morphological change of olfactory bulb is the main reason of dopaminergic degeneration [255–257], others demonstrated that dopamine synthesizing neurons increased in the olfactory bulb, especially in the periglomerular region of patients inflicted wit…”
ResultTompkins, M. M., Basgall, E. J., ZAMRINI, E. Y., & Hill, W. D. (1997) · Europe PMC (PubMed Central) · Cited by 313
Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease
Milnerwood, A. J., & Raymond, L. A. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.08.002 · Cited by 312 · cited 1×
“Another plausible mechanism is that aberrant striatal function could lead to axon degeneration and eventually result in neuronal loss [47,48].”
BackgroundThe role of DAT-SPECT in movement disorders
Kagi, G., Bhatia, K. P., & Tolosa, E. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.157370 · Cited by 311
Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenacre, J. K., & Petrie, A. (1974) · BMJ · doi:10.1136/bmj.4.5942.442 · Cited by 311 · cited 1×
“Due to the complications associated with levodopa, new drugs in the form of dopamine receptor agonists have been developed for patients who have the early stages of PD; these dopamine receptor agonists confer anti-PD therapy with relatively low risk of developing dyskinesia [9–11].”
BackgroundEffect on mood of subthalamic DBS for Parkinson’s disease A consecutive series of 24 patients
Berney, A., Vingerhoets, F., Perrin, A., Guex, P., Villemure, J.-G., Burkhard, P. R., Benkelfat, C., & Ghika, J. (2002) · Neurology · doi:10.1212/01.wnl.0000032756.14298.18 · Cited by 310 · cited 1×
“Recent studies suggest that DBS may cause manic depression, induce emotional instability and suicidal thoughts [221,223,225–230].”
BackgroundSerum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease
Schwarzschild, M. A. (2008) · Archives of Neurology · doi:10.1001/archneur.2008.65.6.nct70003 · Cited by 310
McNaught, K. S. P., Mytilineou, C., JnoBaptiste, R., Yabut, J., Shashidharan, P., Jenner, P., & Olanow, C. W. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00821.x · Cited by 304 · cited 1×
“On the other hand, UCH-L1 acts as an enzyme that recycles ubiquitin in neurons and destruction of UCH-L1 can lead to formation of misfolded proteins [77–79].”
BackgroundHow much phenotypic variation can be attributed to parkin genotype?
Lohmann, E., Periquet, M., Bonifati, V., Wood, N. W., De Michele, G., Bonnet, A., Fraix, V., Broussolle, E., Horstink, M. W. I. M., Vidailhet, M., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10613 · Cited by 301 · cited 1×
“Studies suggest that most of the point mutations are extremely rare and not likely to contribute any major role in PD pathogenesis although parkin mutations are quite prevalent in early onset of PD [71,172,173] and LRRK2 mutations contribute to cause 2% of the sporadic aspects of PD [174,175].”
BackgroundMixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
The Parkinson Study Group PRECEPT Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000277648.63931.c0 · Cited by 292 · cited 2×
“Likewise, CEP-1347 showed promise in animal models [151–153]; however, when evaluated in PD patients in clinical trials, it did not show significant improvement in either resting tremor or cognitive deficit [113].”
BackgroundBrocks, D. R. (1999) · PubMed · Cited by 291
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
Kornhuber, J., Weller, M., Schoppmeyer, K., & Riederer, P. (1994) · PubMed · Cited by 290
Olfaction in neurodegenerative disorder
Hawkes, C. (2003) · Movement Disorders · doi:10.1002/mds.10379 · Cited by 289
Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions
Schapira, A. H. V., & Olanow, C. W. (2004) · JAMA · doi:10.1001/jama.291.3.358 · Cited by 288 · cited 2×
“Moreover, the endpoints need to be chosen carefully so that they are confounded by the symptomatic effects of PD therapeutics [34,35].”
BackgroundTransplanted dopaminergic neurons develop PD pathologic changes: A second case report
Kordower, J. H., Chu, Y., Hauser, R. A., Olanow, C. W., & Freeman, T. B. (2008) · Movement Disorders · doi:10.1002/mds.22369 · Cited by 287 · cited 1×
“Recently, it has been shown that PD subjects who died 10–15 years after the transplant have α-synuclein in the transplanted cells, indicating that implanted cells were also affected by the neurodegenerative processes in the patient’s brain [23,118,233].”
BackgroundKo, H. S., Lee, Y., Shin, J.-H., Karuppagounder, S. S., Gadad, B. S., Koleske, A. J., Pletnikova, O., Troncoso, J. C., Dawson, V. L., & Dawson, T. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006083107 · Cited by 283 · cited 4×
“Thus, when we inhibit the c-Abl activity by imatinib/Gleevec [201], nilotinib/Tasigna [202] or bafetinib/INNO-406 [203], they can bring DA to normal amounts and protect the degeneration of TH loss in the midbrain SN of mice [199,200].”
BackgroundResultInfluentialNeural mechanisms in disorders of movement
Crossman, A. R. (1989) · Comparative Biochemistry and Physiology Part A: Physiology · doi:10.1016/0300-9629(89)90201-6 · Cited by 275 · cited 2×
“Recent ablation studies in animal model of PD and the introduction of the deep brain stimulation technique revolutionized our ability to comprehend about the pathogenesis of PD [15–17,207,208].”
BackgroundMethodNeuropsychological effects of bilateral STN stimulation in Parkinson disease: A controlled study
Smeding, H. M. M., Speelman, J. D., Koning-Haanstra, M., Schuurman, P. R., Nijssen, P., van Laar, T., & Schmand, B. (2006) · Neurology · doi:10.1212/01.wnl.0000234881.77830.66 · Cited by 272
-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells
Smith, W. W. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-05.2005 · Cited by 268 · cited 1×
“Recent evidence also suggests that chemical changes such as oxidation and phosphorylation are essential for accumulation of misfolded protein, α-synuclein [195–197].”
BackgroundSaporito, M. S., Brown, E. M., Miller, M. S., & Carswell, S. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37972-8 · Cited by 266 · cited 1×
“Likewise, CEP-1347 showed promise in animal models [151–153]; however, when evaluated in PD patients in clinical trials, it did not show significant improvement in either resting tremor or cognitive deficit [113].”
BackgroundSynphilin-1 is present in Lewy bodies in Parkinson's disease
Wakabayashi, K., Engelender, S., Yoshimoto, M., Tsuji, S., Ross, C. A., & Takahashi, H. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<521::aid-ana18>3.0.co;2-b · Cited by 266 · cited 1×
“This toxic protein, Lewy bodies, is made of different proteins such as α-synuclein [37,38], synphilin-1 [39], and ubiquitin [40].”
BackgroundLysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity
Qiao, L., Hamamichi, S., Caldwell, K. A., Caldwell, G. A., Yacoubian, T. A., Wilson, S., Xie, Z.-L., Speake, L. D., Parks, R., Crabtree, D., et al. (2008) · Molecular Brain · doi:10.1186/1756-6606-1-17 · Cited by 263
Lotharius, J., Falsig, J., van Beek, J., Payne, S., Dringen, R., Brundin, P., & Leist, M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1746-05.2005 · Cited by 262 · cited 1×
“Likewise, CEP-1347 showed promise in animal models [151–153]; however, when evaluated in PD patients in clinical trials, it did not show significant improvement in either resting tremor or cognitive deficit [113].”
BackgroundBeal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256 · cited 1×
“Another agent that confers neuroprotection at least in animal models is coenzyme Q10 [147].”
BackgroundEffects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
Chung, K. A., Lobb, B. M., Nutt, J. G., & Horak, F. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f6128c · Cited by 252 · cited 1×
“These drugs act by prolonging the effects of acetylcholine in cholinergic pathways by slowing down its metabolism [134,135].”
BackgroundKordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 252
Nitrated alpha‐synuclein‐activated microglial profiling for Parkinson’s disease
Reynolds, A. D., Glanzer, J. G., Kadiu, I., Ricardo‐Dukelow, M., Chaudhuri, A., Ciborowski, P., Cerny, R., Gelman, B., Thomas, M. P., Mosley, R. L., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05087.x · Cited by 244 · cited 1×
“In in vitro studies, it has been recently been reported that different chemical conformation such as nitrated and aggregated forms of α-synuclein can induce microglial activation and eventually release more chemicals that are toxic to cells [88–91].”
BackgroundRationale for and use of NMDA receptor antagonists in Parkinson's disease
Hallett, P. J., & Standaert, D. G. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.04.001 · Cited by 237 · cited 1×
“The most promising glutamate antagonist to protect dopamine neurons against PD should be selective for specific channel subunits to confer neuroprotection [107].”
BackgroundRhee, Y.-H., Ko, J.-Y., Chang, M.-Y., Yi, S.-H., Kim, D., Kim, C.-H., Shim, J.-W., Jo, A.-Y., Kim, B.-W., Lee, H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45794 · Cited by 236
Non-steroidal anti-inflammatory drugs in Parkinson's disease
Esposito, E., Di Matteo, V., Benigno, A., Pierucci, M., Crescimanno, G., & Di Giovanni, G. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.02.008 · Cited by 234 · cited 2×
“are commonly used to treat pain and to treat inflammation; however, in animal studies as well in in vitro, it has been shown that they can also prevent the degeneration of dopaminergic neurons [80].”
BackgroundOlfactory function in atypical parkinsonian syndromes
Wenning, G. K., Shephard, B., Hawkes, C., Petruckevitch, A., Lees, A., & Quinn, N. (1995) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1995.tb06998.x · Cited by 232 · cited 1×
“exploited to demarcate from other neurological diseases such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) but not from multiple system atrophy (MSA) [255,260,261].”
BackgroundLewy bodies in Parkinson's disease are recognized by antibodies to complement proteins
Yamada, T., McGeer, P. L., & McGeer, E. G. (1992) · Acta Neuropathologica · doi:10.1007/bf00427222 · Cited by 231 · cited 1×
“Additionally, recent evidence has suggested that a complementary system may also play a role in PD pathogenesis as elevated levels of complement proteins in Lewy bodies were observed in PD [86,87].”
BackgroundEslamboli, A., Georgievska, B., Ridley, R. M., Baker, H. F., Muzyczka, N., Burger, C., Mandel, R. J., Annett, L., & Kirik, D. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4421-04.2005 · Cited by 231 · cited 1×
“One such trophic factor is glial cell derived neurotrophic factor or GDNF that nourishes dopamine synthesizing neurons of the substantia nigra [116,154].”
BackgroundStriatal mechanisms underlying movement, reinforcement, and punishment
Kravitz, A. V., & Kreitzer, A. C. (2012) · Physiology · doi:10.1152/physiol.00004.2012 · Cited by 224 · cited 1×
“A recent optogenetic study confirms that the neurotransmitter dopamine mainly regulates motor activity by stimulating the neurons in the nigra that project to the striatum and mostly express D1 spiny neurons rather than neurons of the pallidum that project to the striatum, which mostly controls the excitation of the t…”
BackgroundChung, K. K. K., Dawson, V. L., & Dawson, T. M. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01998-6 · Cited by 222 · cited 1×
“On the other hand, UCH-L1 acts as an enzyme that recycles ubiquitin in neurons and destruction of UCH-L1 can lead to formation of misfolded proteins [77–79].”
BackgroundDujardin, K., Defebvre, L., Krystkowiak, P., Blond, S., & Destée, A. (2001) · Journal of Neurology · doi:10.1007/s004150170139 · Cited by 218 · cited 1×
“Both these procedures may some side effects on communication ability and cognitive deficit [215–223]; although verbal fluency and cognitive deficits were more commonly seen in older patients [222,224].”
BackgroundLi, J., Englund, E., Widner, H., Rehncrona, S., Björklund, A., Lindvall, O., & Brundin, P. (2010) · Movement Disorders · doi:10.1002/mds.23012 · Cited by 216 · cited 1×
“Recently, it has been shown that PD subjects who died 10–15 years after the transplant have α-synuclein in the transplanted cells, indicating that implanted cells were also affected by the neurodegenerative processes in the patient’s brain [23,118,233].”
BackgroundImam, S. Z., Zhou, Q., Yamamoto, A., Valente, A. J., Ali, S. F., Bains, M., Roberts, J. L., Kahle, P. J., Clark, R. A., & Li, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1833-10.2011 · Cited by 214 · cited 1×
“We have shown that a prominent non-receptor tyrosine kinase, c-Abl, regulates several cellular processes that may be linked to PD [198].”
BackgroundSelf-citationNeuronal Life-and-Death Signaling, Apoptosis, and Neurodegenerative Disorders
Mattson, M. P. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1997 · Cited by 214
Chauhan, N. B., Siegel, G. J., & Lee, J. M. (2001) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(01)00115-6 · Cited by 207 · cited 7×
“This study raised concerns that the patients developed an antibody against GDNF. Subsequently, a study was conducted in monkeys where large dose of GDNF was administered and significant cell loss was observed in the cerebellum, suggesting an unsafe feature of this trophic factor.”
BackgroundInfluentialSerum Cholesterol Levels and the Risk of Parkinson's Disease
de Lau, L. M. L., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj283 · Cited by 205 · cited 1×
“Recently it has also been demonstrated that low levels of LDL cholesterol can elevate the risk of having PD [181,182], thus it is possible that if we increase the statin level it may mean that greater the level of LDL, lower the risk of PD, again indicating the neuroprotective aspects of the drug.”
BackgroundMIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE
Wang, L. H., & Johnson, E. M. (2008) · Neurology · doi:10.1212/01.wnl.0000324506.93877.5e · Cited by 204
Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells
Wang, X., Perez, E., Liu, R., Yan, L.-J., Mallet, R. T., & Yang, S.-H. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.032 · Cited by 202 · cited 1×
“Reactive oxygen species (ROS), if produced in low concentration, are helpful in regulating cell function as they trigger subsequent important signaling event but when it is produced in excess it can overwhelm antioxidant defenses and may cause oxidative stress [51].”
BackgroundPredictors of cognitive and psychosocial outcome after STN DBS in Parkinson's Disease
Smeding, H. M. M., Speelman, J. D., Huizenga, H. M., Schuurman, P. R., & Schmand, B. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.140012 · Cited by 194 · cited 1×
“Both these procedures may some side effects on communication ability and cognitive deficit [215–223]; although verbal fluency and cognitive deficits were more commonly seen in older patients [222,224].”
BackgroundModelling of Parkinson's disease in mice
Chesselet, M.-F., & Richter, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70227-7 · Cited by 192 · cited 1×
“Finally, it is possible that age and environmental factors together induce cellular stress leading to failure of compensatory mechanism(s) and ultimately clinical Parkinsonism with chronic neuronal dysfunction [42].”
BackgroundCritical issues of clinical human embryonic stem cell therapy for brain repair
Li, J.-Y., Christophersen, N. S., Hall, V., Soulet, D., & Brundin, P. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2007.12.001 · Cited by 192 · cited 2×
“Recently, it has been shown that PD subjects who died 10–15 years after the transplant have α-synuclein in the transplanted cells, indicating that implanted cells were also affected by the neurodegenerative processes in the patient’s brain [23,118,233].”
BackgroundLower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease
Huang, X., Chen, H., Miller, W. C., Mailman, R. B., Woodard, J. L., Chen, P. C., Xiang, D., Murrow, R. W., Wang, Y., & Poole, C. (2007) · Movement Disorders · doi:10.1002/mds.21290 · Cited by 189 · cited 1×
“Recently it has also been demonstrated that low levels of LDL cholesterol can elevate the risk of having PD [181,182], thus it is possible that if we increase the statin level it may mean that greater the level of LDL, lower the risk of PD, again indicating the neuroprotective aspects of the drug.”
BackgroundTargets for neuroprotection in Parkinson's disease
Yacoubian, T. A., & Standaert, D. G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.009 · Cited by 188 · cited 1×
“Conversely, these trophic factors have the ability to act directly on the loss of TH in the brain without affecting non-dopaminergic part of PD [50].”
BackgroundProspects of stem cell therapy for replacing dopamine neurons in Parkinson's disease
Lindvall, O., & Kokaia, Z. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.001 · Cited by 187 · cited 1×
“Unlike ESCs, iPSCs are not hindered by ethical issues [294].”
BackgroundDopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186
Cassarino, D. S., Fall, C. P., Smith, T. S., & Bennett, J. P. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71010295.x · Cited by 183 · cited 1×
“One such D2 receptor agonist is pramipexole, which has the ability to act as an antioxidant due to its chemical structure [137,140].”
BackgroundKitamura, Y., Kosaka, T., Kakimura, J.-I., Matsuoka, Y., Kohno, Y., Nomura, Y., & Taniguchi, T. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.6.1046 · Cited by 181 · cited 1×
“It has been shown that the dopamine receptor agonist can protect against degeneration of TH neurons in both in vitro and in animal models [136–140].”
Pollock, K., Dahlenburg, H., Nelson, H., Fink, K. D., Cary, W., Hendrix, K., Annett, G., Torrest, A., Deng, P., Gutierrez, J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.12 · Cited by 178
Olanow, C. W., Schapira, A. H., LeWitt, P. A., Kieburtz, K., Sauer, D., Olivieri, G., Pohlmann, H., & Hubble, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70602-0 · Cited by 178 · cited 1×
“However, a double blinded randomized human PD clinical trial using this agent did not show any positive result [150].”
BackgroundDeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172 · cited 1×
“Thus, when we inhibit the c-Abl activity by imatinib/Gleevec [201], nilotinib/Tasigna [202] or bafetinib/INNO-406 [203], they can bring DA to normal amounts and protect the degeneration of TH loss in the midbrain SN of mice [199,200].”
BackgroundÅkerud, P., Alberch, J., Eketjäll, S., Wagner, J., & Arenas, E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730070.x · Cited by 172
The nonmotor symptoms of Parkinson's disease—An overview
Lim, S., & Lang, A. E. (2010) · Movement Disorders · doi:10.1002/mds.22786 · Cited by 171 · cited 1×
“However, we cannot rule out the possibility that not only PD pathology is confined to the degeneration of dopaminergic neurons but also include non-motor such as cognitive impairment, hallucinations and other disturbances due to dysfunction of autonomic nervous system also play major role(s) in the array of impairment…”
BackgroundDeep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes
Weaver, F., Follett, K., Hur, K., Ippolito, D., & Stern, M. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.103.6.0956 · Cited by 168 · cited 1×
“It has recently been documented that DBS performed either unilaterally or bilaterally improves parkinsonian motor signs [209,211–214].”
BackgroundPsychosis and Other Psychiatric Manifestations of Levodopa Therapy
Celesia, G. G., & Barr, A. N. (1970) · Archives of Neurology · doi:10.1001/archneur.1970.00480270003001 · Cited by 167 · cited 1×
“Other well-known side effects of L-DOPA include psychosis, hallucinations and other psychiatric manifestations [124]; and hypotension [125].”
BackgroundCastelli, L., Perozzo, P., Zibetti, M., Crivelli, B., Morabito, U., Lanotte, M., Cossa, F., Bergamasco, B., & Lopiano, L. (2006) · European Neurology · doi:10.1159/000093213 · Cited by 167 · cited 1×
“Both these procedures may some side effects on communication ability and cognitive deficit [215–223]; although verbal fluency and cognitive deficits were more commonly seen in older patients [222,224].”
BackgroundThe premotor phase of Parkinson's disease
Tolosa, E., Compta, Y., & Gaig, C. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.06.007 · Cited by 165
Present and future drug treatment for Parkinson's disease
Schapira, A. H. V. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.035980 · Cited by 163 · cited 1×
“The adverse effects included cognitive impairment, constipation and urinary retention issues [133].”
BackgroundDe Gaspari, D. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.078659 · Cited by 163 · cited 1×
“Both these procedures may some side effects on communication ability and cognitive deficit [215–223]; although verbal fluency and cognitive deficits were more commonly seen in older patients [222,224].”
BackgroundWang, J., You, H., Liu, J.-F., Ni, D.-F., Zhang, Z.-X., & Guan, J. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2350 · Cited by 162 · cited 1×
“While a few studies suggest degeneration of olfactory epithelium of morphological change of olfactory bulb is the main reason of dopaminergic degeneration [255–257], others demonstrated that dopamine synthesizing neurons increased in the olfactory bulb, especially in the periglomerular region of patients inflicted wit…”
ResultNeural grafting in Parkinson’s disease
Brundin, P., Barker, R. A., & Parmar, M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84014-2 · Cited by 162
Olfactory function in Parkinsonian syndromes
Müller, A., Müngersdorf, M., Reichmann, H., Strehle, G., & Hummel, T. (2002) · Journal of Clinical Neuroscience · doi:10.1054/jocn.2001.1071 · Cited by 161 · cited 1×
“exploited to demarcate from other neurological diseases such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) but not from multiple system atrophy (MSA) [255,260,261].”
BackgroundBromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro
Ogawa, N., Tanaka, K.-I., Asanuma, M., Kawai, M., Masumizu, T., Kohno, M., & Mori, A. (1994) · Brain Research · doi:10.1016/0006-8993(94)90969-5 · Cited by 160 · cited 1×
“One such D2 receptor agonist is pramipexole, which has the ability to act as an antioxidant due to its chemical structure [137,140].”
Background
Cited by
Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8590578 · Cited by 523
Nakajima, A., & Ohizumi, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143380 · Cited by 235
“The mechanisms that may lead to the degeneration of dopaminergic neurons include oxidative stress, mitochondrial dysfunction, protein aggregation and misfolding, neuroinflammation, excitotoxicity, apoptosis, and loss of trophic factors [54].”
BackgroundEffects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models
Castelli, V., d’Angelo, M., Lombardi, F., Alfonsetti, M., Antonosante, A., Catanesi, M., Benedetti, E., Palumbo, P., Cifone, M. G., Giordano, A., et al. (2020) · Aging · doi:10.18632/aging.102927 · Cited by 162
“In vitro, BDNF counteracted the dopaminergic neurons death, indicating its potential use in the advance of neuroprotective therapeutic approaches for PD [40].”
BackgroundMead, B. P., Kim, N., Miller, G. W., Hodges, D., Mastorakos, P., Klibanov, A. L., Mandell, J. W., Hirsh, J., Suk, J. S., Hanes, J., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b00616 · Cited by 151
Yang, Z., Li, T., Li, S., Wei, M., Qi, H., Shen, B., Chang, R. C.-C., Le, W., & Piao, F. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00460 · Cited by 67
Metadata
- Authors
- Sarkar, S., Raymick, J., & Imam, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-06-08
- Volume
- 17
- Issue
- 6
- Pages
- 904
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2417001119
- Cited by
- 202
- References
- 301
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.